Gabapentin Dosing: Not Weight-Based in Adults
Gabapentin dosing is NOT based on body weight in adults; instead, use fixed-dose titration starting at 100-300 mg and increasing by 100-300 mg every 1-7 days as tolerated, up to a maximum of 3600 mg/day in three divided doses 1.
Adult Dosing Algorithm
The FDA-approved dosing strategy follows a fixed-dose titration approach regardless of patient weight 1:
For Neuropathic Pain (Postherpetic Neuralgia):
- Day 1: 300 mg once daily
- Day 2: 600 mg/day (300 mg twice daily)
- Day 3: 900 mg/day (300 mg three times daily)
- Target maintenance: 1800 mg/day (600 mg three times daily)
- Maximum: 3600 mg/day if needed, though additional benefit above 1800 mg/day is not consistently demonstrated 2, 1
For Epilepsy (Adults ≥12 years):
- Starting dose: 300 mg three times daily
- Maintenance: 300-600 mg three times daily
- Maximum: 2400-3600 mg/day 1
The guideline evidence emphasizes that gabapentin requires careful titration due to nonlinear pharmacokinetics from saturable absorption 2. This is why dosing is based on tolerability and response rather than weight.
Pediatric Dosing (Ages 3-11): Weight-Based
In contrast to adults, pediatric dosing IS weight-based 1:
- Starting dose: 10-15 mg/kg/day in three divided doses
- Maintenance (ages 3-4): 40 mg/kg/day in three divided doses
- Maintenance (ages 5-11): 25-35 mg/kg/day in three divided doses
- Maximum studied: Up to 50 mg/kg/day
- Maximum interval between doses: 12 hours
Critical Dosing Adjustments
Renal Impairment (Essential Modification)
Both gabapentin and pregabalin require mandatory dose reduction in renal insufficiency 2. Adjust based on creatinine clearance 1:
- CrCl ≥60 mL/min: 900-3600 mg/day (standard dosing)
- CrCl 30-59 mL/min: 400-1400 mg/day in 2 divided doses
- CrCl 15-29 mL/min: 200-700 mg/day as single daily dose
- CrCl <15 mL/min: 100-300 mg/day as single daily dose
- Hemodialysis: Maintenance dose based on CrCl + supplemental 125-350 mg post-dialysis
Elderly Patients
Use the same fixed-dose approach but with lower starting doses and slower titration due to age-related decline in renal function 2, 1.
Common Pitfalls to Avoid
Don't calculate adult doses by weight - This is a common error. Adults receive fixed doses titrated to effect, not mg/kg dosing.
Don't rush titration - Gabapentin's nonlinear absorption means rapid escalation increases side effects (dizziness, sedation) without proportional benefit 2.
Don't forget renal adjustment - Failure to reduce doses in renal impairment leads to accumulation and toxicity 2, 1.
Don't exceed 12-hour dosing intervals - Maximum time between doses should not exceed 12 hours to maintain therapeutic levels 1.
Don't abruptly discontinue - Taper over minimum 1 week to avoid withdrawal 1.
Duration of Adequate Trial
An adequate therapeutic trial requires 3-8 weeks for titration plus 2 weeks at maximum tolerated dose - meaning gabapentin assessment can require 2 months or more 2.
Why Not Weight-Based in Adults?
The evidence consistently shows that gabapentin efficacy in adults is demonstrated across a dose range (1800-3600 mg/day) with comparable effects, and higher doses don't consistently provide additional benefit but do increase adverse effects 2. The nonlinear pharmacokinetics mean that absorption becomes saturated at higher doses, making weight-based calculations irrelevant 2. Dosing is therefore optimized by titrating to clinical effect and tolerability rather than targeting a specific mg/kg ratio.